Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherNeuropharmacology

Efficacy of VMAT2 inhibition and synergy with antipsychotics in animal models of schizophrenia

Samuel R. J. Hoare, Andrea E. Kudwa, Rosa Luo and Dimitri E. Grigoriadis
Journal of Pharmacology and Experimental Therapeutics February 23, 2022, JPET-AR-2021-000979; DOI: https://doi.org/10.1124/jpet.121.000979
Samuel R. J. Hoare
1Pharmechanics LLC, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea E. Kudwa
2Neurocrine Biosciences, Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosa Luo
3Crinetics Pharmaceuticals Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dimitri E. Grigoriadis
4Department of Pharmacology & Lead Discovery, Neurocrine Biosciences, Inc., United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dgrigoriadis@neurocrine.com

Data Supplement

  • Supplemental Tables -

    Table S1. PPI Expt 1: RRR-DHTBZ dose response, TBZ and haloperidol data

    Table S2. PPI Expt 2: RRR-DHTBZ dose response and haloperidol data

    Table S3: RRR-DHTBZ Dose Response

    Table S4: RRR-DHTBZ Dose Response

    Table S5: Risperidone – RRR-DHTBZ Combination

    Table S6: Risperidone – RRR-DHTBZ Combination

    Table S7: Risperidone – RRR-DHTBZ Combination

    Table S8: Olanzapine – RRR-DHTBZ Combination

    Table S9: Olanzapine – RRR-DHTBZ Combination

    Table S10: Olanzapine – RRR-DHTBZ Combination

    Table S11: Olanzapine 3 mg/kg

    Table S12: Experiment 1

    Table S13: Experiment 2

  View article

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics